Literature DB >> 16567675

The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.

Ihab R Kamel1, David A Bluemke, John Eng, Eleni Liapi, Wells Messersmith, Diane K Reyes, Jean-Francois H Geschwind.   

Abstract

PURPOSE: To assess treatment response of hepatocellular carcinoma (HCC) after transarterial chemoembolization (TACE) with use of diffusion and dynamic contrast medium-enhanced magnetic resonance (MR) imaging.
MATERIALS AND METHODS: MR imaging studies before and after TACE in 38 patients with HCC (33 male patients and five female patients) were evaluated. Diffusion and dynamic contrast medium-enhanced MR imaging was performed on a 1.5-T unit. The imaging protocol included T2-weighted fast spin-echo, breath-hold diffusion-weighted echoplanar, and breath-hold unenhanced and contrast medium-enhanced T1-weighted three-dimensional fat-saturation gradient-recalled echo imaging in the arterial and portal venous phases. Tumor size, percent enhancement, and apparent diffusion coefficient (ADC) values were recorded before and after treatment. Survival analysis was also performed.
RESULTS: The study included 38 lesions with a mean diameter of 8.0 cm. Mean reduction in tumor diameter was 8 mm after treatment (t test; P = .0005), which did not fulfill Response Evaluation Criteria in Solid Tumors for complete or partial response. Reduction in tumor enhancement in the arterial (30%) and venous (47%) phases was statistically significant (signed-rank test; P = .0003 and P < 0.00005, respectively). Tumor ADC value increased from 0.0015 mm(2)/sec to 0.0018 mm(2)/sec after treatment (t test; P = .026), whereas the ADC values for the liver, spleen, and muscle remained unchanged. Median patient survival was 19 months.
CONCLUSIONS: After TACE, tumors demonstrated decreased size and enhancement with increases in ADC values. In this cohort, diffusion and dynamic contrast medium-enhanced MR imaging parameters were significantly altered after TACE, and these could be useful tools in the assessment of tumor response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567675     DOI: 10.1097/01.RVI.0000200052.02183.92

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  55 in total

1.  Functional magnetic resonance imaging response of targeted tumor burden and its impact on survival in patients with hepatocellular carcinoma.

Authors:  Celia Pamela Corona-Villalobos; Vivek Gowdra Halappa; Susanne Bonekamp; John Eng; Diane Reyes; David Cosgrove; Neda Rastegar; Li Pan; Timothy M Pawlik; Ihab R Kamel
Journal:  Invest Radiol       Date:  2015-04       Impact factor: 6.016

2.  Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy.

Authors:  Wayne L Monsky; Armando S Garza; Isaac Kim; Shaun Loh; Tzu-Chun Lin; Chin-Shang Li; Jerron Fisher; Parmbir Sandhu; Vishal Sidhar; Abhijit J Chaudhari; Frank Lin; Larry-Stuart Deutsch; Ramsey D Badawi
Journal:  Cardiovasc Intervent Radiol       Date:  2010-08-04       Impact factor: 2.740

3.  Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization.

Authors:  Johnathan C Chung; Neel K Naik; Robert J Lewandowski; Jie Deng; Mary F Mulcahy; Laura M Kulik; Kent T Sato; Robert K Ryu; Riad Salem; Andrew C Larson; Reed A Omary
Journal:  World J Gastroenterol       Date:  2010-07-07       Impact factor: 5.742

Review 4.  Applications of molecular imaging.

Authors:  Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

5.  Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.

Authors:  Robert J Lewandowski; Mary F Mulcahy; Laura M Kulik; Ahsun Riaz; Robert K Ryu; Talia B Baker; Saad M Ibrahim; Michael I Abecassis; Frank H Miller; Kent T Sato; Seanthan Senthilnathan; Scott A Resnick; Edward Wang; Ramona Gupta; Richard Chen; Steven B Newman; Howard B Chrisman; Albert A Nemcek; Robert L Vogelzang; Reed A Omary; Al B Benson; Riad Salem
Journal:  Radiology       Date:  2010-06       Impact factor: 11.105

6.  Novel imaging biomarkers of response to transcatheter arterial chemoembolization in hepatocellular carcinoma patients.

Authors:  Sylvain Favelier; Louis Estivalet; Pierre Pottecher; Romaric Loffroy
Journal:  Chin J Cancer Res       Date:  2015-12       Impact factor: 5.087

Review 7.  [Oncological imaging for therapy response assessment].

Authors:  J Stattaus
Journal:  Radiologe       Date:  2014-01       Impact factor: 0.635

Review 8.  Whole-body diffusion-weighted and proton imaging: a review of this emerging technology for monitoring metastatic cancer.

Authors:  Michael A Jacobs; Li Pan; Katarzyna J Macura
Journal:  Semin Roentgenol       Date:  2009-04       Impact factor: 0.800

9.  Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization.

Authors:  Ahsun Riaz; Robert J Lewandowski; Laura Kulik; Robert K Ryu; Mary F Mulcahy; Talia Baker; Vanessa Gates; Ritu Nayar; Ed Wang; Frank H Miller; Kent T Sato; Reed A Omary; Michael Abecassis; Riad Salem
Journal:  Cardiovasc Intervent Radiol       Date:  2009-12-05       Impact factor: 2.740

Review 10.  Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer.

Authors:  Michael A Jacobs; Ronald Ouwerkerk; Kyle Petrowski; Katarzyna J Macura
Journal:  Top Magn Reson Imaging       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.